New Independent Director Added: Dr. Carolyn R. Bertozzi, a scientist, joined the board effective December 8, 2025, bringing scientific expertise to governance oversight Committee Assignments: Dr. Bertozzi will serve on both the Science and Technology Committee and Ethics and Compliance Committee, reinforcing technical and compliance oversight capabilities Neutral Governance Event: The appointment…

Our analysis rates this filing BULLISH. This is a routine, positive governance development with no material concerns. The appointment of Dr. Bertozzi represents a strategic enhancement to Eli Lilly's Board, adding deep scientific and research expertise particularly relevant for a pharmaceutical…

Concern level: LOW (1.0/10).

Notable risk changes: Board elected Dr. Carolyn R. Bertozzi as new independent director effective December 8, 2025 - adds scientific expertise to governance; Dr. Bertozzi will serve on Science and Technology Committee and Ethics and Compliance Committee - strengthens oversight in key areas; New director appointment is routine governance matter with no material negative implications for operations or strategy.

The model predicts LLY will outperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.